Literature DB >> 19506585

The socioeconomic burden of SLE.

Chak Sing Lau1, Anselm Mak.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic, relapsing-remitting, multisystemic autoimmune inflammatory disorder that predominantly affects women of childbearing age. Much has been written about the clinical course and long-term damage associated with SLE, as well as the reduced life expectancy of patients with this condition. In addition, studies have emphasized the socioeconomic and psychosocial impact of SLE, although the monetary cost of caring for patients with the disorder has only been evaluated in a modest number of studies and a restricted number of countries. SLE has a negative impact on quality of life and is associated with high health-care costs and significant productivity loss. Factors associated with increased cost of SLE include long disease duration, high disease activity and damage, poor physical and mental health, and high education and employment levels. Similarly, high disease activity and damage, poor physical health, certain disease manifestations, as well as poor family and social support are associated with poor health-related quality of life outcomes. SLE incurs a great burden on both the patient and society. Long-term prospective studies should be encouraged to monitor the costs and psychosocial impact of this condition, and to better understand the factors that are associated with poor outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19506585     DOI: 10.1038/nrrheum.2009.106

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  49 in total

1.  How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?

Authors:  Meenakshi Jolly
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

2.  Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data.

Authors:  R Ramsey-Goldman; J E Dunn; C F Huang; D Dunlop; J E Rairie; S Fitzgerald; S Manzi
Journal:  Arthritis Rheum       Date:  1999-05

3.  The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs.

Authors:  Pantelis Panopalis; Michelle Petri; Susan Manzi; David A Isenberg; Caroline Gordon; Jean-Luc Senécal; John R Penrod; Lawrence Joseph; Yvan St Pierre; Christian Pineau; Paul R Fortin; Nurhan Sutcliffe; Jean-Richard Goulet; Denis Choquette; Tamara Grodzicky; John M Esdaile; Ann E Clarke
Journal:  Arthritis Rheum       Date:  2007-02-15

Review 4.  A review of health related quality of life in systemic lupus erythematosus.

Authors:  K McElhone; J Abbott; L S Teh
Journal:  Lupus       Date:  2006       Impact factor: 2.911

5.  Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus.

Authors:  Chi Chiu Mok; Chi Hung To; Anselm Mak
Journal:  Medicine (Baltimore)       Date:  2006-07       Impact factor: 1.889

6.  Mortality and causes of death in systemic lupus erythematosus.

Authors:  J Trager; M M Ward
Journal:  Curr Opin Rheumatol       Date:  2001-09       Impact factor: 5.006

7.  The systemic lupus erythematosus tri-nation study: longitudinal changes in physical and mental well-being.

Authors:  P Panopalis; M Petri; S Manzi; D A Isenberg; C Gordon; J-L Senecal; J R Penrod; L Joseph; Y St Pierre; C Pineau; P R Fortin; N Sutcliffe; J-R Goulet; D Choquette; T Grodzicky; J M Esdaile; A E Clarke
Journal:  Rheumatology (Oxford)       Date:  2005-03-09       Impact factor: 7.580

8.  Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.

Authors:  C C Mok; L Y Ho; M Y Cheung; K L Yu; C H To
Journal:  Scand J Rheumatol       Date:  2009 Mar-Apr       Impact factor: 3.641

9.  Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study.

Authors:  C R L Cardoso; F V Signorelli; J A S Papi; G F Salles
Journal:  Lupus       Date:  2008-11       Impact factor: 2.911

Review 10.  Lupus in the developing world--is it any different?

Authors:  Mohammed Tikly; Sandra V Navarra
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-08       Impact factor: 4.098

View more
  41 in total

1.  Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Authors:  William Stohl; Falk Hiepe; Kevin M Latinis; Mathew Thomas; Morton A Scheinberg; Ann Clarke; Cynthia Aranow; Frank R Wellborne; Carlos Abud-Mendoza; Douglas R Hough; Lilia Pineda; Thi-Sau Migone; Z John Zhong; William W Freimuth; W Winn Chatham
Journal:  Arthritis Rheum       Date:  2012-07

2.  The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.

Authors:  Thomas D Szucs; Daniele Puri; Patricia R Blank
Journal:  Eur J Clin Pharmacol       Date:  2014-05-27       Impact factor: 2.953

3.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 4.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

5.  An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL.

Authors:  Jin-Shei Lai; Jennifer L Beaumont; Sally E Jensen; Karen Kaiser; David L Van Brunt; Amy H Kao; Shih-Yin Chen
Journal:  Clin Rheumatol       Date:  2016-11-15       Impact factor: 2.980

6.  Prevalence and incidence of systemic lupus erythematosus in South Korea.

Authors:  Jee-Seon Shim; Yoon-Kyoung Sung; Young Bin Joo; Hye-Soon Lee; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

Review 7.  Global trends, potential mechanisms and early detection of organ damage in SLE.

Authors:  Anselm Mak; David A Isenberg; Chak-Sing Lau
Journal:  Nat Rev Rheumatol       Date:  2012-12-11       Impact factor: 20.543

8.  Associations of HSP90AA2 gene polymorphisms with disease susceptibility, glucocorticoids efficacy and health-related quality of life in Chinese systemic lupus erythematosus patients.

Authors:  Man Zhang; Su-Su Li; Qiao-Mei Xie; Jian-Hua Xu; Xiu-Xiu Sun; Fa-Ming Pan; Sheng-Qian Xu; Sheng-Xiu Liu; Jin-Hui Tao; Shuang Liu; Jing Cai; Pei-Ling Chen; Long Qian; Chun-Huai Wang; Chun-Mei Liang; Hai-Liang Huang; Hai-Feng Pan; Hong Su; Yan-Feng Zou
Journal:  Genes Genomics       Date:  2018-06-15       Impact factor: 1.839

9.  Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare.

Authors:  Melissa E Munroe; Evan S Vista; Joel M Guthridge; Linda F Thompson; Joan T Merrill; Judith A James
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

Review 10.  Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.

Authors:  Giuseppe Turchetti; Jinoos Yazdany; Ilaria Palla; Edward Yelin; Marta Mosca
Journal:  Clin Exp Rheumatol       Date:  2012-10-16       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.